Agenus Inc. (AGEN)
AGENNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$7.07
-0.0779 (-1.09%) today
At the close, Nov 10, 4:00 PM ET. After hours $7.07 +0.74%
- Market cap
- $317.63m
- P/E
- 4.5
- EPS, last 4 quarters
- $1.59
- Dividend yield
- –
- Day range
- $6.64 to $7.13
- 52-week range
- $2.71 to $10.31
- Average volume
- 947.2k
- Previous close
- $7.15
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $25.00, +253.5% from here
Earnings
next estimate $-0.1300Next report
Dec 2025
+144.1%
Mar 2026
-51.4%
Jun 2026
-120.0%
Sep 2026
0.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $30.23m | $34.20m | $33.74m | $34.52m |
| Gross profit | $29.59m | $34.20m | $33.74m | $34.52m |
| Operating income | -$4.54m | $14.40m | $15.05m | $11.29m |
| Net income | $63.91m | -$10.58m | $39.23m | -$550.0k |
Last four quarters: revenue $132.69m, margin 69.3%, free cash flow –
News
8 latest- Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock DownZacks · 4 days ago
- Agenus Inc. Reports Third Quarter 2026 Total Revenue of $31.5 millionFintel · 5 days ago
- Agenus (AGEN) Q3 Earnings Meet EstimatesZacks · 5 days ago
- Agenus Targets Phase 3 Colon Cancer Trial as Financing Hinges on Enrollment MilestonesMarketBeat · 5 days ago
- Agenus Pivots BOT/BAL Strategy to Phase III Colon Cancer TrialMarketBeat · Oct 20, 2026
- Agenus Consensus Price Target Increased by 35.04% to $26.86Fintel · Oct 2, 2026
- Agenus Reports Q2 Profit; Advances BOT+BAL Toward Phase 3 ROBBIN Trial RTTNews · Aug 19, 2026
- ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue EstimatesZacks · Aug 4, 2026
The company
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- agenusbio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.